Oct 13, 2013 – New therapy gives hope to Multiple Sclerosis Patients

Stuart SchlossmanMisc. Research Reports, Multiple Sclerosis

New strategy to treat multiple sclerosis shows promise in mice
New strategy to treat multiple sclerosis shows promise in mice
The new study showed the drug benztropine led to the repair of multiple sclerosis-damaged nerve fibers in animal models. Credit: Luke Lairson, The Scripps Research Institute.

Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. 

Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.


One of the newly identified compounds, a Parkinson’s disease drug called benztropine, was highly effective in treating a standard model of MS in mice, both alone and in combination with existing MS therapies.

“We’re excited about these results, and are now considering how to design an initial clinical trial,” said Luke L. Lairson, an assistant professor of Chemistry at TSRI and senior author of the study, which is reported online in Nature on October 9, 2013.

Lairson cautioned that benztropine is a drug with dose-related adverse side effects, and has yet to be proven effective at a safe dose in human MS patients. “People shouldn’t start using it off-label for MS,” he said.

A New Approach

An autoimmune disease of the brain and spinal cord, MS currently affects more than half a million people in North America and Europe, and more than two million worldwide. Its precise triggers are unknown, but certain infections and a lack of vitamin D are thought to be risk factors. The disease is much more common among those of Northern European heritage, and occurs about twice as often in women as in men.

In MS, immune cells known as T cells infiltrate the upper spinal cord and brain, causing inflammation and ultimately the loss of an insulating coating called myelin on some nerve fibers. As nerve fibers lose this myelin coating, they lose their ability to transmit signals efficiently, and in time may begin to degenerate. The resulting symptoms, which commonly occur in a stop-start, “relapsing-remitting” pattern, may include limb weakness, numbness and tingling, fatigue, vision problems, slurred speech, memory difficulties and depression, among other problems.

Current therapies, such as interferon beta, aim to suppress the immune attack that de-myelinates nerve fibers. But they are only partially effective and are apt to have significant adverse side effects.



To comment – click the comment link shown below

…….
USE OUR SHARE LINKS at the top of this page  – to provide this
article to others
……
REMAIN up to date
with MS News and Education
Visit: www.msviewsandnews.org  to register
…………………….

.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews